钆塞酸增强简化MRI用于肝细胞癌监测:初步经验
单中心回顾性研究纳入330例肝硬化或慢性乙型肝炎患者,行钆塞酸二钠增强简化MRI筛查肝细胞癌,94.2%基线检查诊断充分,141例可分类者中灵敏度0.92、特异度0.91,但57%患者失访。
要点
- 钆塞酸增强简化MRI在肝硬化或慢性乙型肝炎人群中诊断充分率达94.2%。
- 基线检查检出肝细胞癌灵敏度0.92(95%CI 0.62,1.00)、特异度0.91(95%CI 0.84,0.95)。
- 57%患者失访,作者提出需策略提高随访依从性。
核心结论
- 钆塞酸增强简化MRI在临床可行,诊断充分率高,基于初步经验能准确显示高危患者的肝细胞癌。
- 作者提出需要策略提高随访依从性。
研究设计与样本
- 单中心回顾性研究,连续纳入2014年至2016年接受至少一次钆塞酸增强简化MRI监测肝细胞癌的18岁及以上肝硬化或慢性乙型肝炎患者330例。
- 检查由6名腹部放射科医生之一前瞻性判读用于临床诊疗,临床、影像及其他数据从电子病历提取。
- 诊断充分性在所有患者中评估,诊断准确性在可依据复合参考标准分类为有或无肝细胞癌的患者亚组中评估。
诊断标准与关键数值
- 330例患者中311例(94.2%)基线钆塞酸增强简化MRI检查诊断充分。
- 141例(43%)可分类患者中,129例(91.4%)分类为无肝细胞癌,12例(8.6%)分类为有肝细胞癌。
- 基线钆塞酸增强简化MRI检出肝细胞癌的灵敏度为0.92(95%CI 0.62,1.00),特异度为0.91(95%CI 0.84,0.95)。
临床应用与阅片要点
- 原文未据此给出推荐。
局限性
- 本文为单中心初步经验。
- 330例患者中187例(57%)失访。
- 作者提出需要策略提高随访依从性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To describe a single-center preliminary experience with gadoxetate disodium-enhanced abbreviated MRI for hepatocellular carcinoma (HCC) screening and surveillance in patients with cirrhosis or chronic hepatitis B virus (cHBV).
MATERIALS AND METHODS: This was a retrospective study of consecutive patients aged 18 years and older with cirrhosis or cHBV who underwent at least one gadoxetate-enhanced abbreviated MRI examination for HCC surveillance from 2014 through 2016. Examinations were interpreted prospectively by one of six abdominal radiologists for clinical care. Clinical, imaging, and other data were extracted from electronic medical records. Diagnostic adequacy was assessed in all patients. Diagnostic accuracy was assessed in the subset of patients who could be classified as having HCC or not having HCC on the basis of a composite reference standard.
RESULTS: In this study, 330 patients (93% with cirrhosis; 45% women; mean age, 59 years) underwent gadoxetate-enhanced abbreviated MRI. In the 330 patients, 311 (94.2%) baseline gadoxetate-enhanced abbreviated MRI examinations were diagnostically adequate. Of 141 (43%) of the 330 patients, 91.4% (129 of 141) could be classified as not having HCC and 8.6% (12 of 141) could be classified as having HCC. Baseline gadoxetate-enhanced abbreviated MRI had 0.92 sensitivity (95% confidence interval [CI]: 0.62, 1.00) and 0.91 specificity (95% CI: 0.84, 0.95) for detection of HCC. Of the 330 patients who underwent baseline gadoxetate-enhanced abbreviated MRI, 187 (57%) were lost to follow-up.
CONCLUSION: Gadoxetate-enhanced abbreviated MRI is feasible clinically, has a high diagnostic adequacy rate, and, on the basis of our preliminary experience, accurately depicts HCC in high-risk patients. Strategies to enhance follow-up compliance are needed.© RSNA, 2019Keywords: Abdomen/GI, Cirrhosis, Liver, MR-Imaging, Oncology, ScreeningSupplemental material is available for this article.
引用
- Brunsing RL, Chen DH, Schlein A, et al. Gadoxetate-enhanced Abbreviated MRI for Hepatocellular Carcinoma Surveillance: Preliminary Experience. Radiol Imaging Cancer. 2019. PMID: 33778680. doi:10.1148/rycan.2019190010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。